Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
J Enzyme Inhib Med Chem
; 36(1): 147-153, 2021 Dec.
Статья
в английский
| MEDLINE | ID: covidwho-1024061
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease 2019 (COVID-19). Since its emergence, the COVID-19 pandemic has not only distressed medical services but also caused economic upheavals, marking urgent the need for effective therapeutics. The experience of combating SARS-CoV and MERS-CoV has shown that inhibiting the 3-chymotrypsin-like protease (3CLpro) blocks the replication of the virus. Given the well-studied properties of FDA-approved drugs, identification of SARS-CoV-2 3CLpro inhibitors in an FDA-approved drug library would be of great therapeutic value. Here, we screened a library consisting of 774 FDA-approved drugs for potent SARS-CoV-2 3CLpro inhibitors, using an intramolecularly quenched fluorescence (IQF) peptide substrate. Ethacrynic acid, naproxen, allopurinol, butenafine hydrochloride, raloxifene hydrochloride, tranylcypromine hydrochloride, and saquinavir mesylate have been found to block the proteolytic activity of SARS-CoV-2 3CLpro. The inhibitory activity of these repurposing drugs against SARS-CoV-2 3CLpro highlights their therapeutic potential for treating COVID-19 and other Betacoronavirus infections.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Antiviral Agents
/
Cysteine Proteinase Inhibitors
/
Drug Repositioning
/
Coronavirus 3C Proteases
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
Тип исследования:
Прогностическое исследование
Темы:
Традиционная медицина
Пределы темы:
Люди
Язык:
английский
Журнал:
J Enzyme Inhib Med Chem
Тематика журнала:
Биохимия
/
Химия
Год:
2021
Тип:
Статья
Аффилированная страна:
14756366.2020.1850710
Документы, близкие по теме
MEDLINE
...
LILACS
LIS